T. Newcomb

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma

V. Gandhi, C. Quéva, Qingshan Yang, 2015, Clinical Cancer Research.

Mitoxantrone and Paclitaxel Combination Chemotherapy in Metastatic Breast Cancer

W. Urba, R. Ghalie, A. Cartmell, 2001, Cancer investigation.

Idelalisib Treatment Is Associated with Improved Cytopenias in Patients with Relapsed/Refractory iNHL and CLL

G. Salles, I. Flinn, T. Kipps, 2015 .

Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials.

A. Zelenetz, M. Keating, S. O'brien, 2015 .

Outcomes of patients with relapsed and refractory chronic lymphocytic leukemia (CLL) who discontinue idelalisib treatment.

Jeffrey A Jones, A. Pettitt, S. Stilgenbauer, 2016 .

CFU-GEMM correlate with neutrophil and platelet recovery in patients receiving autologous marrow transplantation after high-dose melphalan chemotherapy.

W. Knight, G. Clark, C. Page, 1987, Bone marrow transplantation.

Acute hyperkalemia associated with inhalation of a potent ENaC antagonist: Phase 1 trial of GS-9411.

S. Lewis, D. Warnock, R. Boucher, 2014, Journal of aerosol medicine and pulmonary drug delivery.